Mylan (MYL) Sued by Shareholder Over EpiPen Payments
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Mylan (NASDAQ: MYL) shares are on watch after an investor sued the company over allegations that it made misstatements on payments made to government health-insurance programs with respect to its EpiPen product, according to Bloomberg.
The lawsuit was filed in Manhattan court Tuesday.
Shares of Mylan are down around 1 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan (MYL) Gains on Generic Concerta Approval
- Reading (RDI) Announces Dismissal of Derivative Claims with Prejudice
- Mylan (MYL), Theravance Biopharma(TBPH) Announce Positive Data from Two Revefenacin Phase 3s as COPD Treatment
Create E-mail Alert Related CategoriesInsiders' Blog, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!